Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Cross Above 50-Day Moving Average – Time to Sell?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $78.23 and traded as high as $90.80. Kiniksa Pharmaceuticals International shares last traded at $89.20, with a volume of 2,320,220 shares trading hands.

Wall Street Analyst Weigh In

KNSA has been the subject of several research analyst reports. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. The Goldman Sachs Group raised their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus price target of $98.43.

Kiniksa Pharmaceuticals International Stock Performance

The business’s 50 day moving average is $78.88 and its two-hundred day moving average is $59.78. The firm has a market capitalization of $7.61 billion, a PE ratio of 75.05 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The firm had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.16 EPS for the current year.

Insider Buying and Selling

In other news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently modified their holdings of the company. Headlands Technologies LLC bought a new position in Kiniksa Pharmaceuticals International in the second quarter valued at $1,161,000. Inspire Investing LLC purchased a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at about $1,698,000. OMERS ADMINISTRATION Corp bought a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $631,000. Handelsbanken Fonder AB bought a new stake in Kiniksa Pharmaceuticals International during the second quarter worth about $1,343,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Kiniksa Pharmaceuticals International by 56.7% during the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock worth $3,050,000 after purchasing an additional 22,917 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.